Xencor

Xencor Receivables

The Accounts Receivable of Xencor (XNCR) as of Nov 2, 2026 is 60.85 M USD. In the previous year, Accounts Receivable was 23.74 M USD — a change of 156.33% (higher).

Receivables

60.85 MUSD

YoY

156.33%

Last updated:

Accounts Receivable of Xencor is 2024 60.85 M USD. Accounts Receivable of Xencor was 2023 23.74 M USD. It decreases by 156.33% higher compared to the previous year.

The Xencor Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
1.10 M USD
Jan 1, 2018
10.20 M USD
Jan 1, 2019
21.60 M USD
Jan 1, 2020
23.90 M USD
Jan 1, 2021
66.40 M USD
Jan 1, 2022
29.00 M USD
Jan 1, 2023
23.74 M USD
Jan 1, 2024
60.85 M USD
The Xencor Receivables history
YEARReceivablesYoY
60.85 MUSD+156.33%
23.74 MUSD-18.14%
29.00 MUSD-56.33%
66.40 MUSD+177.82%
23.90 MUSD+10.65%
21.60 MUSD+111.76%
10.20 MUSD+827.27%
1.10 MUSD-87.21%
8.60 MUSD—
0.00USD-100.00%
3.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Xencor Stock analysis

What does Xencor do? The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xencor stock

Accounts Receivable of Xencor is 60.85 M USD in 2024.

Accounts Receivable of Xencor changed from 23.74 M USD to 60.85 M USD, representing a 156.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Xencor since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Xencor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Xencor

All Key Metrics — Xencor